Sphingosine 1-phosphate and its type 1 G protein-coupled receptor:: trophic support and functional regulation of T lymphocytes

被引:26
作者
Goetzl, EJ [1 ]
Gräler, MH [1 ]
机构
[1] Univ Calif San Francisco, Dept Med & Microbiol Immunol, San Francisco, CA 94143 USA
关键词
lysophospholipids; immunity; chemotaxis; FTY720;
D O I
10.1189/jlb.1103567
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The lysophospholipid (LPL) growth factors sphingosine 1-phosphate (S1P) and lysophosphatidic acid (LPA) are generated by macrophages, dendritic cells, mast cells, and platelets, which leads to lymph and plasma concentrations of 0.1-1 muM. Distinctive profiles of G protein-coupled receptors (GPCRs) for S1P and LPA are expressed by each type of immune cell and are regulated by cellular activation. At 1-100 nM, S1P signals T cells through their principal S1P, GPCRs with consequent protection from apoptosis, enhancement of chemotaxis, and facilitation of optimal regulatory activity of CD4(+)25(+) T cells. At 0.3-3 muM, S1P inhibits T cell chemotaxis and to a lesser extent other functions. These S1P-S1P(1) GPCR signals suppress homing of blood and spleen T cells to secondary lymphoid tissues. S1P(1) GPCR antagonists evoke lymphopenia by permitting blood T cells to enter lymph nodes and blocking S1P(1) GPCR-dependent T cell efflux from lymph nodes. Inversely, there is a decrease in lymphoid tissue traffic of T cells in transgenic mice, which overexpress lymphocyte S1P(1) GPCRs. The immunotherapeutic activity of S1P(1) GPCR antagonists, which limits T cell access to organ grafts and autoimmune antigens, does not reduce other functional capabilities of T cells. LPLs and their GPCRs thus constitute an immunoregulatory system of sufficient prominence for pharmacological targeting in transplantation, autoimmunity, and immunodeficiency.
引用
收藏
页码:30 / 35
页数:6
相关论文
共 23 条
  • [1] An SZ, 1998, J CELL BIOCHEM, P147
  • [2] The immune modulator FTY720 targets sphingosine 1-phosphate receptors
    Brinkmann, V
    Davis, MD
    Heise, CE
    Albert, R
    Cottens, S
    Hof, R
    Bruns, C
    Prieschl, E
    Baumruker, T
    Hiestand, P
    Foster, CA
    Zollinger, M
    Lynch, KR
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (24) : 21453 - 21457
  • [3] FTY720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity
    Brinkmann, V
    Lynch, KR
    [J]. CURRENT OPINION IN IMMUNOLOGY, 2002, 14 (05) : 569 - 575
  • [4] FTY720 alters lymphocyte homing and protects allografts without inducing general immunosuppression
    Brinkmann, V
    Chen, S
    Feng, L
    Pinschewer, D
    Nikolova, Z
    Hof, R
    [J]. TRANSPLANTATION PROCEEDINGS, 2001, 33 (1-2) : 530 - 531
  • [5] International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature
    Chun, J
    Goetzl, EJ
    Hla, T
    Igarashi, Y
    Lynch, KR
    Moolenaar, W
    Pyne, S
    Tigyi, G
    [J]. PHARMACOLOGICAL REVIEWS, 2002, 54 (02) : 265 - 269
  • [6] Transduction of multiple effects of sphingosine 1-phosphate (S1P) on T cell functions by the S1P1 G protein-coupled receptor
    Dorsam, G
    Graeler, MH
    Seroogy, C
    Kong, Y
    Voice, JK
    Goetzl, EJ
    [J]. JOURNAL OF IMMUNOLOGY, 2003, 171 (07) : 3500 - 3507
  • [7] Amelioration of experimental autoimmune encephalomyelitis in lewis rats by FTY720 treatment
    Fujino, M
    Funeshima, N
    Kitazawa, Y
    Kimura, H
    Amemiya, H
    Suzuki, S
    Li, XK
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 305 (01) : 70 - 77
  • [8] FUNGAL METABOLITES .11. A POTENT IMMUNOSUPPRESSIVE ACTIVITY FOUND IN ISARIA-SINCLAIRII METABOLITE
    FUJITA, T
    INOUE, K
    YAMAMOTO, S
    IKUMOTO, T
    SASAKI, S
    TOYAMA, R
    CHIBA, K
    HOSHINO, Y
    OKUMOTO, T
    [J]. JOURNAL OF ANTIBIOTICS, 1994, 47 (02) : 208 - 215
  • [9] Cutting edge: Differential constitutive expression of functional receptors for lysophosphatidic acid by human blood lymphocytes
    Goetzl, EJ
    Kong, Y
    Voice, JK
    [J]. JOURNAL OF IMMUNOLOGY, 2000, 164 (10) : 4996 - 4999
  • [10] Goetzl EJ, 1999, J IMMUNOL, V162, P2049